Skip to content
MatchScript
Menu

Head-to-head · The Match Score

Eden vs Nu Image Medical

Both scored on the same six-factor Match Score. Eden wins this matchup with a 87 to 55 edge.

Higher Match Score

Eden

#7 · Grade B+

People who prioritize a vetted, high-transparency, high-touch provider over the lowest sticker price.

Visit Eden
VS

Nu Image Medical

#379 · Grade C

People who want mainstream telehealth GLP-1 access.

Visit Nu Image Medical

Factor by factor

The six sub-scores behind each Match Score. The quiz reweights these to your priorities — one provider can pull ahead for you on the factors you care about.

Budget Fit
74
48
Speed to Start
90
64
Formulary Match
80
46
Support Level
94
70
Flexibility
90
55
Transparency
92
46

Price, coverage & formulary

DetailEdenNu Image Medical
Semaglutide$239/moNot disclosed
Tirzepatide$349/moNot disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjectable onlyInjectable only
Match Score87 · B+55 · C
Winner: Eden

Eden edges out Nu Image Medical, 87 to 55 on the default Match Score. A polished, high-disclosure compounded program with strong nationwide coverage and hands-on support.

Nu Image Medical is still a fair pick if its strengths line up with yours — best for: People who want mainstream telehealth GLP-1 access.

Worth a look either way: our overall #1 pick is CoreAge Rx (Match Score 91) — nationwide access, both molecules at one flat price, easy to cancel. Or take the 6-question quiz to see your personalized match.

Assume any provider we list may compensate us, at no cost to you. It never changes the Match Score.

Full Eden reviewFull Nu Image Medical review

More head-to-heads

Or browse alternatives to Eden and all comparisons.

Pricing, states and verification reflect each provider's public disclosures at last review; the Match Score and its sub-scores are our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.